Long-Acting Antipsychotic Medications

被引:9
|
作者
Baweja, Raman [2 ]
Sedky, Karim [1 ]
Lippmann, Steven [3 ]
机构
[1] Drexel Univ, Friends Hosp, Philadelphia, PA 19124 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA 17033 USA
[3] Univ Louisville, Louisville, KY 40202 USA
关键词
Injectable antipsychotic medications; depot neuroleptic agents; haloperidol decanoate; fluphenazine decanoate; long-acting risperidone; paliperidone palmitate; long-acting olanzapine; INJECTABLE RISPERIDONE; FLUPHENAZINE DECANOATE; SCHIZOPHRENIC OUTPATIENTS; HALOPERIDOL DECANOATE; DEPOT ANTIPSYCHOTICS; ORAL ANTIPSYCHOTICS; SAFETY; TRIAL; INPATIENTS; ADHERENCE;
D O I
10.2174/138945012799499785
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antipsychotic medicines are the cornerstone pharmacotherapy for patients with psychotic disorders. Early and continuous management of psychoses improves the quality of life, decreases hospitalization and reduces medical costs. However, many psychotic patients are not fully compliant with treatment, and thus they more often experience a relapsing course with a suboptimal clinical outcome. Long-term parenteral antipsychotic agents may improve compliance by offering clear evidence of medication non-compliance and documented drug administration monitoring. Using injection therapy might be especially beneficial to poorly compliant individuals with their first-psychotic episode and those with severe psychopathology or comorbid substance abuse. The availability of five different antipsychotic drug depot medications offers diverse treatment options which can be individualized for each case.
引用
收藏
页码:555 / 560
页数:6
相关论文
共 50 条
  • [1] The Pharmacokinetics of Long-Acting Antipsychotic Medications
    Spanarello, Stefano
    La Ferla, Teresa
    CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (03): : 310 - 317
  • [2] Who receives long-acting antipsychotic medications?
    Glazer, William M.
    PSYCHIATRIC SERVICES, 2007, 58 (04) : 437 - 437
  • [3] Barriers to utilizing long-acting injectable antipsychotic medications
    Getzen, Hayley
    Beasley, Marie
    D'Mello, Dale A.
    ANNALS OF CLINICAL PSYCHIATRY, 2014, 26 (01) : 33 - 38
  • [4] Long-Acting Injectable Antipsychotic Medications in Pregnancy: A Review
    O'Sullivan, Deirdre L.
    Byatt, Nancy
    Dossett, Emily C.
    JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2022, 63 (01): : 53 - 60
  • [5] Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications
    Stroup, T. Scott
    Bareis, Natalie A.
    Rosenheck, Robert A.
    Swartz, Marvin S.
    McEvoy, Joseph P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (01)
  • [6] CHARACTERISTICS OF MEDICARE PATIENTS INITIATING LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS
    Grabner, M.
    Harris, K.
    Chiang, Y. Y.
    Teng, C. C.
    Dosreis, S.
    VALUE IN HEALTH, 2024, 27 (06) : S232 - S233
  • [7] Antipsychotic long-acting injections
    O'Connor, Nick
    AUSTRALASIAN PSYCHIATRY, 2013, 21 (02) : 176 - 177
  • [8] Antipsychotic Long-acting Injections
    Livingston, Martin
    PSYCHIATRIC BULLETIN, 2011, 35 (11): : 438 - 439
  • [9] Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications
    Black, Rachel M.
    Ma, Feiyun
    Hudzik, Anthony A.
    Shepherd, Greene
    Ferreri, Stefanie
    Ozawa, Sachiko
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2023, 63 (03) : 742 - +
  • [10] A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS
    Velligan, Dawn
    Sajatovic, Martha
    SCHIZOPHRENIA BULLETIN, 2020, 46 : S322 - S323